IMMURON Common Stock Net 2018-2024 | IMRN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

IMMURON common stock net from 2018 to 2024. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

IMMURON common stock net from 2018 to 2024. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$231B
Amgen (AMGN)	$161.4B
Gilead Sciences (GILD)	$139.9B
Vertex Pharmaceuticals (VRTX)	$96.3B
Bristol Myers Squibb (BMY)	$93.3B
CSL (CSLLY)	$83.8B
GSK (GSK)	$76.1B
Regeneron Pharmaceuticals (REGN)	$61.5B
Alnylam Pharmaceuticals (ALNY)	$54.9B
Argenex SE (ARGX)	$41.3B
BioNTech SE (BNTX)	$26.7B
Royalty Pharma (RPRX)	$21.3B
Insmed (INSM)	$21.2B
Biogen (BIIB)	$19.5B
Incyte (INCY)	$15.2B
Illumina (ILMN)	$15B
Genmab (GNMSF)	$14.7B
Genmab (GMAB)	$14.2B
BioMarin Pharmaceutical (BMRN)	$11.9B
Ascendis Pharma (ASND)	$11.4B
QIAGEN (QGEN)	$11.1B
Moderna (MRNA)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Exelixis (EXEL)	$10.1B
Verona Pharma American Depositary Share (VRNA)	$9B
Exact Sciences (EXAS)	$8.9B
Bio-Techne Corp (TECH)	$8.6B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$7.9B
Halozyme Therapeutics (HALO)	$7.5B